**3rd Translational Research Conference**
**CHRONIC LYMPHOCYTIC LEUKAEMIA**
March 8-10, 2024 – Vienna, Austria
Chairpersons: Jennifer Brown (Boston), Paolo Ghia (Milan), Michael Hallek (Cologne)

## Friday, March 8, 2024

| | | |
|---|---|---|
| **08:15–08:25** | **Welcome** | Conference Chairpersons |

**SESSION I – CLL disease progression**
**Chairs:** Susan Slager (Rochester), Carsten Niemann (Copenhagen)

| | | |
|---|---|---|
| 08:25-08:30 | Introduction | Susan Slager (Rochester)<br>Carsten Niemann (Copenhagen) |
| 08:30-08:45 | Is Low Count MBL a Precursor to CLL? | Susan Slager (Rochester) |
| 08:45-08:50 | *Discussion* | |
| 08:50-09:05 | Mutated and unmutated IGVH CLL: two different diseases? Why do they respond differently to therapies? | Paolo Ghia (Milan) |
| 09:05-09:10 | *Discussion* | |
| 09:10-09:25 | Focusing on stereotyped B cell receptors in CLL | Kostas Stamatopoulos (Thessaloniki) |
| 09:25-09:30 | *Discussion* | |
| 09:30-09:45 | Genetic evolution of CLL under therapeutic selection | Justin Taylor (Miami) |
| 09:45-09:50 | *Discussion* | |
| 09:50-09:57 | Brief oral communication<br>The evolutionary dynamics of CLL and its impact on outcome | Martí Duran-Ferrer (Barcelona) |
| 09:57-10:00 | *Discussion* | |
| 10:00-10:30 | *Panel discussion* | |
| ***10:30-11:00*** | ***Coffee break*** | |

**SESSION II – Richter's Syndrome**
**Chairs:** Elisa ten Hacken (New York), William Wierda (Houston)

| | | |
|---|---|---|
| 11:00-11:05 | Introduction | Elisa ten Hacken (New York)<br>William Wierda (Houston) |

| | | |
|---|---|---|
| 11:05-11:20 | Modeling Richter's Syndrome | Elisa ten Hacken (New York) |
| 11:20-11:25 | *Discussion* | |
| 11:25-11:40 | Genomics of Richter's; are the seeds of RS present at diagnosis? | Elias Campo (Barcelona) |
| 11:40-11:45 | *Discussion* | |
| 11:45-12:00 | Therapy of Richter Transformation | Toby Eyre (Oxford) |
| 12:00-12:05 | *Discussion* | |
| 12:05-12:12 | Brief oral communication<br>Defining common genomic and transcriptomic profiles in Richter's syndrome paves the way for drug repurposing strategies | Francesco Edoardo Vallone (Turin) |
| 12:12-12:15 | *Discussion* | |
| 12:15-12:45 | *Panel discussion* | |
| ***12:45-14:55*** | ***Lunch*** | |

**13:45-14:45** **SATELLITE SYMPOSIUM**

**Finite Therapy, Infinite Possibilities in CLL: Exploring the Rapid Emergence of Newer Time-limited BTKi Combinations**

**Speakers**: Stephan Stilgenbauer (Ulm), Matthew Davids (Boston), Lydia Scarfò (Milan)

*This symposium is organized by PeerView and supported by AstraZeneca*

**SESSION III – Biomarkers: where do we stand**
**Chairs:** Andrew Rawstron (Leeds), Martina Seiffert (Heidelberg)

| | | |
|---|---|---|
| 14:55-15:00 | Introduction | Andrew Rawstron (Leeds)<br>Martina Seiffert (Heidelberg) |
| 15:00-15:15 | Are del(17p) with concurrent *TP53* mutation, and isolated *TP53* mutation really equivalent? | Sarka Pospisilova (Brno) |
| 15:15-15:20 | *Discussion* | |
| 15:20-15:35 | Genomic complexity by NGS, how does it relate to karyotype? | Pauline Robbe (Oxford) |
| 15:35-15:40 | *Discussion* | |
| 15:40-15:55 | MRD: How do we measure it? Should NGS become the standard? | Andrew Rawstron (Leeds) |
| 15:55-16:00 | *Discussion* | |
| 16:00-16:07 | Brief oral communication<br>The ncBAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia | Blaž Oder (Stockholm) |
| 16:07-16:10 | *Discussion* | |
| 16:10-16:40 | *Panel discussion* | |
| ***16:40-17:10*** | ***Coffee break*** | |

**SESSION IV – Targeting the microenvironment in CLL**
**Chairs:** Adrian Wiestner (Bethesda), Michael Hallek (Cologne)

| | | |
|---|---|---|
| 17:10-17:15 | Introduction | Adrian Wiestner (Bethesda)<br>Michael Hallek (Cologne) |
| 17:15-17:30 | Antitumor immunity in the lymphoid microenvironment | Martina Seiffert (Heidelberg) |
| 17:30-17:35 | *Discussion* | |
| 17:35-17:50 | Metabolism reprogramming in the CLL lymph node | Eric Eldering (Amsterdam) |
| 17:50-17:55 | *Discussion* | |
| 17:55-18:10 | Genetic modulation of the TME in animal models | Hien Nguyen (Cologne) |
| 18:10-18:15 | *Discussion* | |
| 18:15-18:30 | Preclinical rationale for combining bispecific antibodies with targeted therapy for CLL | Adrian Wiestner (Bethesda) |
| 18:30-18:35 | *Discussion* | |
| 18:35-18:42 | Brief oral communications<br>Co-culture with CD40L, IL4 and IL21 expressing stromal cells induces robust CLL cell proliferation in vitro and in PDX co-transplantations | Marek Mraz (Brno) |
| 18:42-18:45 | *Discussion* | |
| 18:45-19:15 | *Panel discussion* | |
| **19:20-20:30** | **Mentored Poster Walks and Welcome Get-together for all participants**<br>Leaders (Biology): Hien Nguyen (Cologne), Elisa ten Hacken (New York)<br>Leaders (Clinical): Arnon Kater (Amsterdam), Andrew Rawstron (Leeds) | |

## Saturday, March 9, 2024

**09:00-10:00** **Simultaneous Meet the Expert sessions**

| | | |
|---|---|---|
| 1. | Pathogenesis and Transformation | Martina Seiffert (Heidelberg) |
| 2. | TP53 where are we standing? | Sarka Pospisilova (Brno)<br>Jitka Malcikova (Brno) |
| 3. | Microenvironment and therapeutic options | Michael Hallek (Cologne) |

***10:00-10:30*** ***Coffee break***

**SESSION V – What is the best time-limited therapy**
**Chairs:** Barbara Eichhorst (Cologne), Arnon Kater (Amsterdam)

| | | |
|---|---|---|
| 10:30-10:35 | Introduction | Barbara Eichhorst (Cologne)<br>Arnon Kater (Amsterdam) |
| 10:35-10:50 | Venetoclax antibody combinations | Barbara Eichhorst (Cologne) |
| 10:50-10:55 | *Discussion* | |
| 10:55-11:10 | BTK – BCL-2 combinations | Carsten Niemann (Copenhagen) |
| 11:10-11:15 | *Discussion* | |
| 11:15-11:30 | Defined duration vs MRD driven time-limited therapy | William Wierda (Houston) |
| 11:30-11:35 | *Discussion* | |
| 11:35-11:42 | Brief oral communication<br>Differential preclinical activity of Bruton tyrosine kinase inhibitors (BTKis) against BTK resistance-associated mutations | Matthew Davids (Boston) |
| 11:42-11:45 | *Discussion* | |
| 11:45-12:15 | *Panel discussion* | |
| ***12:15-14:25*** | ***Lunch*** | |
| **13:15-14:15** | **SATELLITE SYMPOSIUM**<br>**New avenues to improving outcomes for CLL patients**<br>**Chair:** Philipp Staber (Vienna)<br>**Speakers**: Gianluca Gaidano (Novara), Barbara Eichhorst (Cologne)<br>*This symposium is organized and sponsored by BeiGene* | |

**SESSION VI – BTK inhibitors**
**Chairs:** Richard Furman (New York), Paolo Ghia (Milan)

| | | |
|---|---|---|
| 14:25-14:30 | Introduction | Richard Furman (New York)<br>Paolo Ghia (Milan) |
| 14:30-14:45 | Choosing a covalent BTK inhibitor | Richard Furman (New York) |
| 14:45-14:50 | *Discussion* | |
| 14:50-15:05 | What role will non-covalent BTK inhibitors play? | William Wierda (Houston) |
| 15:05-15:10 | *Discussion* | |
| 15:10-15:17 | Brief oral communication<br>TRIM24 expression and regulation in Chronic Lymphocytic Leukaemia upon BTK inhibition | Charalampos Xanthopoulos (Belfast) |
| 15:17-15:20 | *Discussion* | |
| 15:20-15:50 | *Panel discussion* | |
| ***15:50-16:20*** | ***Coffee break*** | |

**SESSION VII – Small molecule resistance**
**Chairs:** Jennifer Woyach (Columbus), Jennifer Brown (Boston)

| | | |
|---|---|---|
| 16:20-16:25 | Introduction | Jennifer Woyach (Columbus)<br>Jennifer Brown (Boston) |
| 16:25-16:40 | Resistance to covalent BTK inhibitors | Jennifer Woyach (Columbus) |
| 16:40-16:45 | *Discussion* | |
| 16:45-17:00 | Resistance to non-covalent BTK inhibitors | Jennifer Brown (Boston) |
| 17:00-17:05 | *Discussion* | |
| 17:05-17:20 | Is there a non-genetic adaptation to BCR inhibitors? | Marek Mraz (Brno) |
| 17:20-17:25 | *Discussion* | |
| 17:25-17:40 | Venetoclax resistance | Lukas P. Frenzel (Cologne) |
| 17:40-17:45 | *Discussion* | |
| 17:45-17:52 | Brief oral communication<br>Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) that progressed in the ALPINE study | Jennifer Brown (Boston) |
| 17:52-17:55 | *Discussion* | |
| 17:55-18:25 | *Panel discussion* | |

## Sunday, March 10, 2024

**08:00-09:00 Meet the Expert Session**

| | | |
|---|---|---|
| 1. | Combination therapies | Barbara Eichhorst (Cologne) |
| 2. | Future therapies including CAR-T therapies | William Wierda (Houston) |
| 3. | Patient selection for time limited versus continued therapy | Jennifer Woyach (Columbus) |

**SESSION VIII – Next generation therapies**
**Chairs:** Tanya Siddiqi (Duarte), Marek Mraz (Brno)

| | | |
|---|---|---|
| 09:10-09:15 | Introduction | Tanya Siddiqi (Duarte)<br>Marek Mraz (Brno) |
| 09:15-09:30 | Beyond venetoclax: other BH3 mimetic therapies | Matthew Davids (Boston) |
| 09:30-09:35 | *Discussion* | |
| 09:35-09:50 | Bispecific antibodies for CLL | Arnon Kater (Amsterdam) |
| 09:50-09:55 | *Discussion* | |
| 09:55-10:10 | CAR-T cell immunotherapy for CLL | Tanya Siddiqi (Duarte) |
| 10:10-10:15 | *Discussion* | |

| | | |
|---|---|---|
| 10:15-10:22 | Brief oral communication<br>Epcoritamab in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results From the CLL Expansion Cohort of EPCORE CLL-1 | Arnon Kater (Amsterdam) |
| 10:22-10:25 | *Discussion* | |
| 10:25-10:55 | *Panel discussion* | |
| ***10:55-11:25*** | ***Coffee break*** | |

**SESSION IX – The future: other targets**
**Chairs:** Jennifer Brown (Boston), Michael Hallek (Cologne)

| | | |
|---|---|---|
| 11:25-11:30 | Introduction | Jennifer Brown (Boston)<br>Michael Hallek (Cologne) |
| 11:30-11:45 | PKC beta | James Blachly (Columbus) |
| 11:45-11:50 | *Discussion* | |
| 11:50-12:05 | Is there hope for PI3K inhibitors? | Jennifer Brown (Boston) |
| 12:05-12:10 | *Discussion* | |
| 12:10-12:25 | NK CAR | Rafet Basar (Houston) |
| 12:25-12:30 | *Discussion* | |
| 12:30-12:45 | Treatment options for “double refractory” CLL | Michael Hallek (Cologne) |
| 12:45-12:50 | *Discussion* | |
| 12:50-12:57 | Brief oral communication<br>Specific antitumor activity of the new SERCA inhibitor CAD204520 in lymphoproliferative disorders with NOTCH1 PEST domain mutations | Elisa Cerretani (Ferrara) |
| 12:57-13:00 | *Discussion* | |
| 13:00-13:30 | *Panel discussion* | |
| ***13:30-13:40*** | ***Closing remarks*** | Conference Chairpersons |

**MEETING CLOSURE**